갈라파고스(GLPG) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

🏛️

거래 정지 중인 종목 2026-06-04 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.

GLPG

Galapagos NV ADR

$27.73

-1.08 ▼ -3.75%

갈라파고스(GLPG) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.8B

스몰캡

P/E

4.7

저평가 구간

배당수익률

없음

52주 위치

23%

저점 +12% · 고점 -27%

애널리스트

보유

B-

Fundamental health

vs. Biotechnology 소형주

수익성

Top 6%

성장

Top 38%

밸류에이션

Top 90%

재무 안정

Top 40%

Index ⓘ	-	P/E ⓘ	4.65	EPS (ttm) ⓘ	5.96	Insider Own ⓘ	25.35%	Shs Outstand ⓘ	65.9M	Perf Week ⓘ	-0.36%
Market Cap ⓘ	1.83B	Forward P/E ⓘ	-	EPS next Y ⓘ	19.26%	Insider Trans ⓘ	-	Shs Float ⓘ	49.2M	Perf Month ⓘ	-4.02%
Enterprise Value ⓘ	-1.69B	PEG ⓘ	-	EPS next Q ⓘ	-0.82	Inst Own ⓘ	22%	Short Float ⓘ	2.79%	Perf Quarter ⓘ	-16.93%
Income ⓘ	0.39B	P/S ⓘ	1.42	EPS this Y ⓘ	-137.86%	Inst Trans ⓘ	-11.44%	Short Ratio ⓘ	9.08	Perf Half Y ⓘ	-8.96%
Sales ⓘ	1.28B	P/B ⓘ	0.48	EPS next 5Y ⓘ	-	ROA ⓘ	9.45%	Short Interest ⓘ	1.37M	Perf YTD ⓘ	-15.2%
Book/sh ⓘ	57.67	P/C ⓘ	0.52	EPS past 3/5Y ⓘ	-	ROE ⓘ	11.51%	52W High ⓘ	-26.6% ($37.78)	Perf Year ⓘ	7.48%
Cash/sh ⓘ	53.43	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	70.43% 18.16%	ROIC ⓘ	10.32%	52W Low ⓘ	12.11% ($24.74)	Perf 3Y ⓘ	-35.35%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	396.11%	Gross Margin ⓘ	97.43%	Volatility(W/M) ⓘ	2.01% 1.87%	Perf 5Y ⓘ	-63.05%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-1.31	Sales Y/Y TTM ⓘ	331.24%	Oper. Margin ⓘ	44.13%	ATR (14) ⓘ	0.72	Perf 10Y ⓘ	-39.51%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	19.96	EPS Q/Q ⓘ	3271.88%	Profit Margin ⓘ	30.58%	RSI (14) ⓘ	36.52	Recom ⓘ	3.11
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	20.11	Sales Q/Q ⓘ	1201.99%	SMA20 ⓘ	-2.99% ($28.58)	Beta ⓘ	0.25	Target Price ⓘ	$33.11
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	2026/5/6	SMA50 ⓘ	-8.55% ($30.32)	Rel Volume ⓘ	1.91	Prev Close ⓘ	$28.81
Employees ⓘ	452	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	126.27% -72.1%	SMA200 ⓘ	-13.74% ($32.15)	Avg Volume(3M) ⓘ	0.15M	Price ⓘ	$27.73
IPO ⓘ	2008/7/7	Option/Short ⓘ	Yes/Yes			Trades ⓘ	3880	Volume ⓘ	288,106	Change ⓘ	-3.75%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Galapagos NV ADR (GLPG) Investment Analysis

What kind of company is Galapagos NV ADR?

갈라파고스(GLPG) 가치주

Healthcare · Biotechnology

Healthcare Stocks

🧬 An innovative Belgian-based biotech company developing next-generation CAR-T cell therapies and novel drugs for autoimmune diseases. It possesses proprietary 'decentralized manufacturing platform' technology capable of producing therapies in just 7 days, and is pursuing aggressive pipeline expansion backed by a massive cash position exceeding €3 billion.

Learn more about Galapagos NV ADR →

Market Cap

$1.8B

Approx. KRW 2.5 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank2146

Employees452people

IPO2008/07/07

Current Price$27.73 ≈ 37,990원

NASD · Belgium

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후

🔔 Earnings release 2026년 2월 23일 (월) · 장 마감 후 EPS +11057.4% 매출 +1166.2%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

44.1%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -210.9% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

30.6%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 소형주 Median -187.6% · Top 13%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

97.4%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 소형주 Median 84.9% · Top 12%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

11.5%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 소형주 Median -37.5% · Top 12%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

9.4%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -21.8% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

10.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -25.0% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

20.11

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

19.96

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$33.11

현재가 대비 +19.4%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+19.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+5589.5%

평균 서프라이즈

2026.05.06

상회

실적 $0.21 · 예상 $-0.97 +121.6%

2026.02.23

상회

+11057.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-137.9%

매우 부진

My positionBottom 5%

Low range Average High range

가치주 소형주 Median 4.4% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+19.3%

양호

My positionMid-range

Low range Average High range

가치주 소형주 Median 8.6% · Top 28%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+18.2%

우수

My positionTop 25%

Low range Average High range

가치주 소형주 Median 12.0% · Top 25%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+1202.0%

우수

My positionTop 5%

Low range Average High range

가치주 소형주 Median 4.2% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -131%p below the market

GLPG -63.0% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-131.4%p

Significantly behind the market

vs Health Care (XLV)

-87.5%p

Significantly behind the sector average

1-year basis

vs S&P 500

-8.5%p

slightly behind the market

vs Health Care (XLV)

-12.2%p

behind the sector average

Rank among peers

5-year return Lower-Mid (lower 48%) Based on 123 peers

1-year return Lower-Mid (lower 29%) Based on 154 peers

Current position within 52-week range

Low (-12.1%p) High (-26.6%p)

Current price is 12.1% above the 52-week low and 26.6% below the 52-week high

Recent risk (last 75 trading days)

Max drawdown

-19.9%

Annualized volatility

26.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 88-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-05-15

Downtrend zone

Current price $27.03 below the midline ($28.23). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

⚡

Current diagnosis · 2026-05-15

Death cross — bearish reversal signal

MACD(-0.588) crossed below Signal(-0.581). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-05-15

Bearish zone

RSI 37.9 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 0.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

4.65x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 7.65x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.48x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 소형주 median 3.34x · Top 1% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

1.42x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 소형주 median 14.61x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$33.11 vs. current price +19.4%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow shows some pressure

Institutional net selling -11.4% · Short interest light 2.8% · Short interest up +0.8pp over last 75d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-11.4%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 22.0%

Moderate institutional participation

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 25.4%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 52.6%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

2.8%

Low — limited short-side pressure

Healthcare 소형주 Median 11.2%

Past 75 days 📈 +0.8%p increase

Short interest days to cover

9.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 65.9M주

Float (tradable shares) 49.2M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 75 days.

ETFs holding GLPG

ETFs with the highest weightings · 10 total shown

SBIO

ALPS Medical Breakthroughs ETF

1.42%

$202M

IBB

iShares Biotechnology ETF

0.10%

$9.4B

DIVG

Invesco S&P 500 High Dividend Growers ETF

0.07%

$11M

GRPZ

Invesco S&P SmallCap 600 GARP ETF

0.07%

$3M

KLMN

Invesco MSCI North America Climate ETF

0.07%

$2.3B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
GLPG This Stock	$1.8B	4.7 ▲	0.5 ▲	11.51% ▲	-	-3.8%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 갈라파고스(GLPG)?

갈라파고스(GLPG) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of GLPG?

The market cap of GLPG is approximately $1.8B, ranking 2,146 within its sector.

What is the P/E ratio of GLPG?

GLPG has a P/E ratio of approximately 4.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for GLPG?

GLPG has recorded a 52-week high of $37.78 and a low of $24.74.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.